HBGRF yields 116.96% · PFE yields 6.13%● Live data
📍 HBGRF pulled ahead of the other in Year 1
Combined, HBGRF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HBGRF + PFE for your $10,000?
Heidelberger Druckmaschinen Aktiengesellschaft, together with its subsidiaries, manufactures, sells, and deals in printing press and other print media industry products in Europe, the Middle East, Africa, Asia/Pacific, Eastern Europe, North America, and South America. The company operates through Print Solutions, Packaging Solutions, and Technology Solutions segments. It offers printing machines, including digital, offset, narrow web, screen, and inline-flexo printing, as well as remarketed equipment; and finishing equipment comprising cutting, die-cutting and embossing, folding, inspection, folding carton gluing, hot foil stamping, and shingled folding. The company also provides technical services, such as installation and relocation, maintenance and cleaning, remote support, repair, and overhauling services, as well as service parts; and performance services consisting of performance evaluation, color management, training, upgrades and retrofits, monitoring, output optimization, print shop optimization, and investment planning. In addition, it offers financial services; and consumables, such as plates, films, chemicals, proofing, glues, digital and analog engraving, blankets, inks, dampening rollers, coatings, varnishes, blankets, rollers, pressroom chemicals, cutting knives, banderoles, ink duct foils, wash-up cloths and spray powders, dispersion glues, binding glues, stitching wires and sealing threads, and folding carton gluing supplies. Further, the company provides software solutions. The company was formerly known as Schnellpressenfabrik AG Heidelberg and changed its name to Heidelberger Druckmaschinen Aktiengesellschaft in 1967. Heidelberger Druckmaschinen Aktiengesellschaft was founded in 1850 and is based in Heidelberg, Germany.
Full HBGRF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.